Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib in Advanced Foregut Neuroendocrine Tumors
NCT02420691Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in foregut neuroendocrine tumor (NET), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2015; status: completed.
02
Drugs
ribociclib
03
Conditions
foregut neuroendocrine tumor (NET)
Beyond the preview
Go deeper on NCT02420691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420691.